Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2

BACKGROUND: Eptinezumab 100 mg and 300 mg met the primary efficacy endpoint in both PROMISE clinical trials, significantly reducing frequency of monthly migraine days over Weeks 1‒12. The objective of this analysis was to assess the clinical response to eptinezumab 100 mg and 300 mg within the pivot...

Descripción completa

Detalles Bibliográficos
Autores principales: Apelian, Rami, Boyle, Lee, Hirman, Joe, Asher, Divya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014586/
https://www.ncbi.nlm.nih.gov/pubmed/35436857
http://dx.doi.org/10.1186/s10194-022-01418-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014586/
https://www.ncbi.nlm.nih.gov/pubmed/35436857
http://dx.doi.org/10.1186/s10194-022-01418-8

Ejemplares similares